Skip to main content

Minutes from Annual General Meeting 2020

Written by Customer Service on . Posted in Public Companies.


On 22 April 2020 at 3:00 pm CET an ordinary general meeting was held in Oncology Venture A/S at Pharmakon Konferencecenter, Milnersvej 42, 3400 Hillerød, Denmark.The agenda for the annual general meeting was as follows:





Resumé and complete resolutionsRe 1Attorney-at-law Lars Lüthjohan Jensen was elected as chairman of the general meeting.Re 2Chief Financial Officer, Henrik Moltke reported on the Company’s activities for the year ended December 31, 2019.Chief Financial Officer, Henrik Moltke also reported on the Company’s financial position as the Company had lost more than half its equity, cf. Danish Companies Act section 119.Re 3The Annual Report was adopted and a resolution was passed to discharge the Board of Directors and Management from liability.Re 4It was resolved that the consolidated loss for the year of EUR 138,132,000 be carried forward to next year.
Re 5The following persons were re-elected for a term expiring at the annual general meeting to be held in 2021:Duncan Moore
Frank Knudsen
Steve Carchedi
Steen Knudsen
Gunnar Magnus Persson
Carani Sanjeeviso that the composition of the Board of Directors remained unchanged.  Information about the current board members was made available on the Company’s website www.oncologyventure.com.Re 6PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-appointed as the Company’s auditor.Re 7The Board of Directors had proposed 2 amendments to the Articles of Association, which were all adopted on the general meeting with the required majority. Each of the resolutions is described below in A and B.Resolution A:It was resolved to amend the Articles of Association by inserting a new authorization in Article 6.10 which authorizes the Board of Directors to issue convertible loan notes which give the right to subscribe for shares in the Company.It was specifically resolved that a new Article 6.10 is inserted in the Articles of Association with the following wording:”The board of directors is authorized until the period ending 1 April 2025 at one or more times by resolution of the board of directors to obtain loans of up to SEK 100,000,000 against issuance of convertible loan notes which give the right to subscribe for shares in the company as well as carry out the appurtenant capital increases without pre-emption rights for the existing shareholders. The loans shall be paid in cash. The terms of the convertible loan notes issued under this authorization shall be determined by the board of directors. The convertible loan notes shall be offered at a conversion price no lower than the market price of the company’s shares.As a consequence of this authorization the board of directors is also authorized until the period ending 1 April 2025 to increase the share capital of the company without pre-emption rights for the existing shareholders by up to a nominal value of DKK 5,000,000 by conversion of the convertible loan notes issued under the authorization set out in this section 6.10.The new shares issued based on this authorization shall be negotiable instruments issued in the name of the holder and registered in the name of the holder in the company’s register of shareholders. The new shares shall not have any restrictions as to their transferability and no shareholder shall be obliged to have the shares redeemed fully or partly. The shares will have the same rights as the existing shares. All other terms are set by the board of directors.”The resolution was adopted at the general meeting with the required majority of at least two thirds of both the votes cast and of the voting share capital represented at the general meeting.Resolution B:It was resolved to amend the Articles of Association by renewing the existing authorization in Article 7.2 that authorizes the Board of Directors to increase the Company’s share capital at one or more times without pre-emption rights for the existing shareholders.It was specifically resolved that the existing wording in Article 7.2 of the Articles of Association is replaced in its entirety with the following wording:
“The board of directors is authorised until the period ending 1 April 2025 at one or more times to increase the company’s share capital by up to nominal DKK 8,000,000. The capital increase shall be carried out without pre-emption rights for the company’s existing shareholders. The new shares may be issued at market price or at a discount price as decided by the board of directors. The board of directors decides that the capital increase is carried out by way of cash contributions, contributions in kind and/or conversion of debt. Sections 7.3 and 7.4 shall apply to the new shares. All other terms are set by the board of directors.”The resolution was adopted at the general meeting with the required majority of at least nine tenths of both the votes cast and of the voting share capital represented at the general meeting.—oo0oo—
Pharmakon Konferencecenter, Milnersvej 42, 3400 Hillerød, DenmarkLars Lüthjohan Jensen
Chairman of the meeting.AttachmentOncology Venture_2020 AGM Minutes

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.